Citation

Nolte SH, Der Lahn MA. Internist. Prax. 2010; 50(1): 173-182.

Copyright

(Copyright © 2010, E U H Marseille Verlag)

DOI

unavailable

PMID

unavailable

Abstract

The amelioration in research, development and licensing of drugs in children is an important issue, but not in a blind creed in progress, but also in the sense of a renouncement to or restriction of an uncritical use on the whole. Data concerning efficacy, safety and dosage which were gained in adults cannot just be transferred to children who are not just small adults. Different age group have special pharmacodynamic and -kinetic properties. Pediatric pharmacotherapy should remain in pediatric hands and should be applied with uppermost restriction and high responsability. Not only for pedagogic reasons pharmacotherapy should be avoided wherever possible - "living without drugs" should be taken serious.

Language: de

Keywords

human; suicide; law; review; antiarrhythmic agent; antidepressant agent; neuroleptic agent; drug intoxication; childhood disease; practice guideline; diazepam; paracetamol; drug safety; phytotherapy; drug industry; economic aspect; drug cost; drug efficacy; drug research; antihistaminic agent; drug distribution; respiratory tract disease; phenobarbital; phenytoin; drug absorption; antibiotic agent; salicylic acid; suxamethonium; antiemetic agent; cyclosporin A; drug therapy; penicillin G; hospital cost; antibiotic therapy; drug bioavailability; antitussive agent; treatment duration; pharmacogenetics; pharmacodynamics; Missing data; Pharmakotherapyin children; Therapeutic abstinence; Underreporting